p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator

Carcinogenesis

Volumn 22, Issue 10, 2001, Pages 1607-1614

  Abeysinghe, Rajeewa D ^a   Greene, Bryan T ^a   Haynes, Robin ^a   Willingham, Mark C ^a   Turner, Jolyn ^a   Planalp, Roy P ^b   Brechbiel, M W ^c   Torti, Frank M ^a   Torti, Suzy V ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Univ of New Hampshire   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; ECDYSONE; ETOPOSIDE; IRON; IRON CHELATING AGENT; MUTANT PROTEIN; PROTEIN P21; PROTEIN P53; TACHPYRIDINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOCHEMISTRY; BREAST CANCER; BREATHING; CANCER CELL CULTURE; CELL DEATH; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG SENSITIVITY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IRON DEFICIENCY; LUNG CANCER; MICROSCOPY; NICK END LABELING; NULL CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; STAINING; TIME; TUMOR CELL CULTURE; TUMOR GROWTH;

EID: 0034787555     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/22.10.1607     Document Type: Article

References (54)

1. Transferrin and transferrin receptors in carcinoma of the breast
2. Transferrin receptor expression by human bladder transitional cell carcinomas
3. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents
4. Potential of iron chelators as effective antiproliferative agents
5. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: The mechanism of action 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone
6. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice
7. Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor
8. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor
9. Deferoxamine: A reversible S-phase inhibitor of human lymphocyte proliferation
10. Effects of a single course of deferoxamine in neuroblastoma patients
11. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines
12. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts
13. An improved synthesis of cis,cis-1,3,5-triaminocyclohexane
14. Tumor cell cytotoxicity of a novel metal chelator
15. Novel iron complexes and chelators based on cis,cis-1,3,5-triaminocyclohexane: Iron-mediated ligand oxidation and biochemical properties
16. Apoptosis during iron chelator-induced differentiation in F9 embryonal carcinoma cells
17. Iron chelators induce apoptosis in proliferating cells
18. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines
19. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells
20. Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13
21. p53: Puzzle and paradigm
22. p53, the cellular gatekeeper for growth and division
23. Mechanisms of p53-mediated apoptosis
24. The p53 tumour suppressor gene
25. Database of p53 gene somatic mutations in human tumors and cell lines
26. Apoptosis in cancer therapy: Crossing the threshold
27. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
28. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
29. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs
30. Ecdysone-inducible gene expression in mammalian cells and transgenic mice
31. Cytochemical methods for the detection of apoptosis
32. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
33. DNA fragmentation is a late event in apoptosis
34. Analytical and pharmacokinetic studies in mice with tachpyr
35. A caspase-activated DNase that degrades DNA during apoptosis and its inhibitor ICAD
36. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis
37. Detection of the initial stages of DNA fragmentation in apoptosis
38. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents
39. Regulation of p53 downstream genes
40. Regulation of p53 by hypoxia: Dissociation of transcriptional repression and apoptosis from p53-dependent transactivation
41. Iron deprivation and cancer: A view beginning with studies of monoclonal antibodies against the transferrin receptor
42. Iron withholding: A defense against infection and neoplasia
43. Role of deferoxamine in tumor therapy
44. The development of iron chelating drugs
45. Translation of ferritin light and heavy subunit mRNAs is regulated by intracellular chelatable iron levels in rat hepatoma cells
46. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha
47. Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction
48. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro
49. Metalloregulation of the tumor suppressor protein p53: Zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells
50. Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound
51. Stress signals utilize multiple pathways to stabilize p53
52. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation
53. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest
54. The polyproline region of p53 is required to activate apoptosis but not growth arrest